Persistent astrocytic IL-3 stimulation of microglia slows disease in Alzheimer’s:treatment perspectives for Alzheimer’s  

作　　者：Natja Haag Hans Zempel 

机构地区：[1]Institute of Human Genetics,Medical Faculty,RWTH Aachen University,Aachen,Germany [2]Institute of Human Genetics,Faculty of Medicine and University Hospital Cologne,University of Cologne,Cologne,Germany [3]Center for Molecular Medicine Cologne(CMMC),Faculty of Medicine and University Hospital Cologne,University of Cologne,Cologne,Germany

出　　处：《Signal Transduction and Targeted Therapy》2021年第12期3369-3370,共2页信号转导与靶向治疗（英文）

基　　金：This research was funded by the Else-Kröner-Fresenius Stiftung(2019_A41);the Jürgen-Manchot-Stiftung and was supported by the Koeln Fortune Program/Faculty of Medicine,University of Cologne(assigned to HZ);a START-grant from the RWTH/University Hospital Aachen assigned to NH.

摘　　要：In their new paper,McAlpine and colleagues provide compelling evidence that astrocyte dependent microglial stimulation is crucial for fighting off one of the most prominent Alzheimer disease(AD)pathological hallmarks,namelyβ-amyloid(Aβ)plaque deposition.They find that(i)a subpopulation of astrocytes secrete the classical cytokine interleukin-3(IL-3),(ii)microglia are responsive to this cytokine,(iii)responsiveness(not so much secretion of IL-3)is increased in patients with AD and model systems of AD,and(iv)presence of IL-3 is necessary to allow microglia to counteract some of the detrimental effects of AD:if IL-3 is missing,AD pathology worsens(see Fig.1 for graphical depiction).1 AD and related tauopathies,e.g.,frontotemporal dementia(FTD)or frontotemporal lobar degeneration with tauopathy(FTLDTAU),are detrimental diseases,impose a huge burden on patients and caregivers,and are the scourge of modern healthcare systems.Despite recent advances in(immuno-)therapies,a causative cure seems out of range.

关 键 词：STIMULATION ALZHEIMER DEGENERATION 

分 类 号：R749[医药卫生—神经病学与精神病学]